New strategies for early detection and prevention of gastric cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, prospective cohort study aims to enroll at least 600 patients diagnosed with primary gastric cancer, around 50 patients with premalignant gastric lesions, and 600 healthy participants in Spain. The study will collect clinical data and biological samples to evaluate clinical, endoscopic, and molecular approaches for identifying individuals at high risk for gastric cancer. By utilizing advanced diagnostic tools and life habits surveys, the study seeks to implement preventive measures that could reduce mortality through early detection and intervention.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults over 18 years-old.
* EDGAR 1 cohort: symptomatic patients undergoing a diagnostic gastroscopy for a prevalence study of PGLs.
* EDGAR 2 cohort: PGLs and early GC with indication for endoscopic resection.
* EPIGASTRIC cohort: patients diagnosed with GC.
* CONTROL cohort: patients without gastric pathology or a familial history of GC, obtained from the EDGAR 1.

Exclusion Criteria:

* Refusal of the patient to participate in the study.
* Medical, psychological or legal inability of the patient to enter the study.
* EDGAR1: Previous diagnosis of PGLs, previous gastric surgery, contraindication for gastroscopy or taking biopsies.
* EDGAR 2: Contraindication for resection/biopsy.
* EPIGASTRIC: gastric neoplasm other than adenocarcinoma.

Where it's running

• Hospital Comarcal de Inca
  Palma de Mallorca, Balearic Islands, Spain Recruiting
• Hospital de Llevant
  Porto Cristo, Balearic Islands, Spain Recruiting
• Hospital Clínic de Barcelona
  Barcelona, Barcelona, Spain Recruiting
• Hospital General de Granollers
  Granollers, Barcelona, Spain Recruiting
• Consorci Sanitari de Terrassa
  Terrassa, Barcelona, Spain Recruiting
• Hospital Santos Reyes
  Aranda de Duero, Burgos, Spain Recruiting

Study contacts

• Study coordinator: Leticia Moreira, MD, PhD
• Email: LMOREIRA@clinic.cat
• Phone: +34 932275400

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Direct injection of a modified vaccinia virus (vvDD-hIL2) into abdominal and gastrointestinal tumors

  This trial will try a single direct injection of a modified vaccinia virus (vvDD-hIL2) into abdominal tumors to see if it is safe for adults with advanced metastatic gastrointestinal or peritoneal cancers who have not responded to standard treatments.

  Recruiting Phase 1 Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Pittsburgh, Pennsylvania · NCT07001592

• Detecting gastric preneoplasia and cancer using blood biomarkers

  This study is testing whether certain blood markers can help find early signs of stomach cancer in people with existing stomach problems and healthy individuals.

  Recruiting at 5 sites Institut Pasteur · Boulogne-Billancourt and 7 other locations · NCT05854368

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

• Epinephrine concentrations during gastric submucosal dissection in adults with gastric neoplasia

  This trial tests whether a lower dose of epinephrine (1:100,000) during gastric ESD works as well as a higher dose (1:500,000) to keep procedures efficient and safe in adults with gastric dysplasia or neoplasia.

  Recruiting Unidade Local de Saúde do Alto Ave, EPE · Guimarães, Braga District · NCT07920068

• Neoadjuvant trastuzumab, durvalumab, and FLOT for HER2-positive gastric or GEJ cancer

  This study tests a pre-surgery treatment combining trastuzumab, durvalumab, and FLOT for patients with HER2-positive locally advanced gastric or gastroesophageal junction cancer to see how many achieve complete tumor disappearance.

  Recruiting Phase 2 Samsung Medical Center · Seoul, Gang-Nam · NCT07911280

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.